PULMONX CORP (LUNG) Stock Price, Quote, News and Overview
NASDAQ:LUNG - Nasdaq - US7458481014 - Common Stock - Currency: USD
LUNG Quote, Performance and Key Statistics
NASDAQ:LUNG (2/21/2025, 11:33:19 AM)
8.925
+0.15 (+1.65%)
The current stock price of LUNG is 8.925 USD. In the past month the price increased by 44.88%. In the past year, price decreased by -18.78%.
LUNG Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.93 | 234.30B | ||
| ISRG | INTUITIVE SURGICAL INC | 82.59 | 215.91B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.98 | 155.30B | ||
| SYK | STRYKER CORP | 31.77 | 147.63B | ||
| MDT | MEDTRONIC PLC | 16.84 | 115.30B | ||
| BDX | BECTON DICKINSON AND CO | 16.4 | 65.52B | ||
| EW | EDWARDS LIFESCIENCES CORP | 28.33 | 43.77B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.35 | 41.75B | ||
| IDXX | IDEXX LABORATORIES INC | 40.5 | 37.31B | ||
| DXCM | DEXCOM INC | 54.03 | 34.82B | ||
| RMD | RESMED INC | 26.23 | 34.06B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.35 | 23.80B |
Related stock screener links
About LUNG
Company Profile
Pulmonx Corp. is a medical technology company, which engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. The company is headquartered in Redwood City, California and currently employs 279 full-time employees. The company went IPO on 2020-10-01. The firm provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its solutions, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat severe emphysema patients. The StratX Platform is a cloud-based quantitative CT analysis service that offers physicians with a report that is designed for its solution, which includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation and has been validated in multiple randomized controlled clinical trials.
Company Info
PULMONX CORP
700 Chesapeake Dr
Redwood City CALIFORNIA 94063 US
CEO: Glendon E. French
Employees: 279
Company Website: https://pulmonx.com/
Investor Relations: https://investors.pulmonx.com/
Phone: 16509342600
PULMONX CORP / LUNG FAQ
What is the stock price of PULMONX CORP today?
The current stock price of LUNG is 8.925 USD. The price increased by 1.65% in the last trading session.
What is the ticker symbol for PULMONX CORP stock?
The exchange symbol of PULMONX CORP is LUNG and it is listed on the Nasdaq exchange.
On which exchange is LUNG stock listed?
LUNG stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PULMONX CORP stock?
12 analysts have analysed LUNG and the average price target is 11.82 USD. This implies a price increase of 32.38% is expected in the next year compared to the current price of 8.925. Check the PULMONX CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PULMONX CORP worth?
PULMONX CORP (LUNG) has a market capitalization of 352.45M USD. This makes LUNG a Small Cap stock.
How many employees does PULMONX CORP have?
PULMONX CORP (LUNG) currently has 279 employees.
What are the support and resistance levels for PULMONX CORP (LUNG) stock?
PULMONX CORP (LUNG) has a support level at 5.59. Check the full technical report for a detailed analysis of LUNG support and resistance levels.
Is PULMONX CORP (LUNG) expected to grow?
The Revenue of PULMONX CORP (LUNG) is expected to grow by 18.72% in the next year. Check the estimates tab for more information on the LUNG EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PULMONX CORP (LUNG) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LUNG, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LUNG, evaluating the profitability, health, valuation and growth aspects
- PULMONX CORP (LUNG) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PULMONX CORP (LUNG) Sales and EPS estimates to see what analysts future expectations are.
- PULMONX CORP (LUNG) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PULMONX CORP (LUNG) Insider and Institutional Ownership to learn about the owners and their transactions.
- PULMONX CORP (LUNG) Stock Chart to make your own analysis
- PULMONX CORP (LUNG) Latest news and press-releases to stay up to date.
Does PULMONX CORP (LUNG) stock pay dividends?
LUNG does not pay a dividend.
When does PULMONX CORP (LUNG) report earnings?
PULMONX CORP (LUNG) will report earnings on 2025-04-29, after the market close.
What is the Price/Earnings (PE) ratio of PULMONX CORP (LUNG)?
PULMONX CORP (LUNG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.4).
What is the Short Interest ratio of PULMONX CORP (LUNG) stock?
The outstanding short interest for PULMONX CORP (LUNG) is 3.24% of its float. Check the ownership tab for more information on the LUNG short interest.
LUNG Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to LUNG. When comparing the yearly performance of all stocks, LUNG turns out to be only a medium performer in the overall market: it outperformed 59.84% of all stocks.
LUNG Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LUNG. LUNG scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
LUNG Financial Highlights
Over the last trailing twelve months LUNG reported a non-GAAP Earnings per Share(EPS) of -1.4. The EPS increased by 12.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.11% | ||
| ROE | -60.8% | ||
| Debt/Equity | 0.4 |
LUNG Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to LUNG. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of -16.35% and a revenue growth 18.72% for LUNG